Literature DB >> 19098058

Immediate versus deferred coronary angioplasty in non-ST-segment elevation acute coronary syndromes.

R K Riezebos1, E Ronner, E Ter Bals, T Slagboom, P C Smits, J M ten Berg, F Kiemeneij, G Amoroso, M S Patterson, M J Suttorp, J G P Tijssen, G J Laarman.   

Abstract

BACKGROUND: The field of acute coronary syndromes is characterised by an increasing tendency towards early invasive catheter-based diagnostics and therapeutics-a practice based on observational and retrospective data.
OBJECTIVE: To compare immediate versus deferred angioplasty in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS)
METHODS: A randomised, prospective multicentre trial was performed in patients admitted with NSTE-ACS, eligible for percutaneous coronary intervention (PCI). Interim analysis was performed after enrolment of 251 patients; PCI was appropriate in 142 patients. These patients were randomised to immediate PCI (n = 73) or deferred PCI (24-48 h) (n = 69). Patients received protocol-driven glycoprotein IIb/IIIa blockers, aspirin and clopidogrel. The primary end point was a composite of death, non-fatal myocardial infarction (MI) or unplanned revascularisation, at 30 days. After hospital discharge outpatient follow-up was performed at 30 days and 6 months.
RESULTS: The incidence at 30 days of the primary end point was 60% in the group receiving immediate PCI and 39% in the group receiving deferred PCI (relative risk (RR) = 1.5, 95% CI 1.09 to 2.15; p = 0.004). No deaths occurred in either group. MI was significantly more common in the group receiving immediate PCI (60% vs 38%, RR = 1.6, 95% CI 1.12 to 2.28, p = 0.005). Unplanned revascularisation was similar in both groups. The observed difference was preserved over 6-months' follow-up.
CONCLUSIONS: Immediate PCI was associated with an increased rate of MI in comparison with a 24-48 h deferred strategy, despite aggressive antithrombotic treatment. The results suggest that PCI for high-risk patients with non-refractory NSTE-ACS should be delayed for at least 24 h after hospital admission. TRIAL REGISTRATION NUMBER: ISRCTN80874637.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19098058     DOI: 10.1136/hrt.2008.154815

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  29 in total

Review 1.  Routine invasive versus conservative management in non-ST-elevation acute coronary syndromes.

Authors:  Peter R Sinnaeve
Journal:  J Cardiovasc Transl Res       Date:  2011-11-01       Impact factor: 4.132

2.  Cardiovascular Diagnosis and Therapy (CDT) Editorial: the Minimalist Immediate Mechanical Intervention study.

Authors:  Muhammad Aetesam-Ur-Rahman; Colin Berry
Journal:  Cardiovasc Diagn Ther       Date:  2017-06

3.  The value of coronary CT angiography in the evaluation of non-ST-elevation myocardial infarction.

Authors:  R K Riezebos
Journal:  Heart Asia       Date:  2011-01-01

4.  Prime time for the sweet spot in timing of coronary invasive approach in patients with non-ST elevation myocardial infarction.

Authors:  Eliano P Navarese; Bernhard Wernly; Michael Lichtenauer; Martino Pepe; Wojciech Wanha; Giuseppe Ferrante; Lara Frediani; Verena Veulemans; Tobias Zeus; Ralf Westenfeld; Christian Jung; Paul A Gurbel
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

5.  Timing of invasive strategy in patients with non-ST-segment elevation acute coronary syndrome and effect on clinical outcomes.

Authors:  Vladan Vukcevic; Goran Stankovic
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

6.  Influence of the Timing of Percutaneous Coronary Intervention on Clinical Outcomes in Non-ST-Elevation Myocardial Infarction.

Authors:  Kamuran Tekin; Caglar Emre Cagliyan; Ibrahim Halil Tanboga; Mehmet Balli; Onur Kadir Uysal; Bugra Ozkan; Osman Ziya Arik; Murat Cayli
Journal:  Korean Circ J       Date:  2013-11-30       Impact factor: 3.243

7.  Evaluating the optimal timing of revascularisation in patients with transient ST-segment elevation myocardial infarction: rationale and design of the TRANSIENT Trial.

Authors:  Jorrit Lemkes; Robin Nijveldt; Aernout M Beek; Paul Knaapen; Alexander Hirsch; Joost Meijers; Cor P Allaart; Albert van Rossum; Niels van Royen
Journal:  J Cardiovasc Transl Res       Date:  2014-05-30       Impact factor: 4.132

8.  [Timing of invasive treatment in NSTEMI: as fast as in STEMI?].

Authors:  A Jobs; I Eitel; S Desch
Journal:  Herz       Date:  2014-09       Impact factor: 1.443

9.  Acute kidney injury requiring dialysis and in-hospital mortality in patients with chronic kidney disease and non-ST-segment elevation acute coronary syndrome undergoing early vs delayed percutaneous coronary intervention: A nationwide analysis.

Authors:  Brijesh Patel; Philip Carson; Mahek Shah; Lohit Garg; Manyoo Agarwal; Sahil Agrawal; Shilpkumar Arora; Susan Steigerwalt; Anthony Bavry; Raman Dusaj; Nainesh Patel; Bruce Feldman
Journal:  Clin Cardiol       Date:  2017-12-20       Impact factor: 2.882

10.  Prognostic benefit from an early invasive strategy in patients with non-ST elevation acute coronary syndrome (NSTEACS): evaluation of the new risk stratification in the NSTEACS European guidelines.

Authors:  Jesús Martinón-Martínez; Belén Álvarez Álvarez; Teba González Ferrero; Federico García-Rodeja Arias; Óscar Otero García; Carla Cacho Antonio; Charigan Abou Jokh Casas; Pilar Zuazola; Alberto Cordero; David Escribano; Belén Cid Alvarez; Diego Iglesias Álvarez; Rosa Agra Bermejo; Pedro Rigueiro Veloso; José María García Acuña; Francisco Gude Sampedro; José Ramón González Juanatey
Journal:  Clin Res Cardiol       Date:  2021-03-09       Impact factor: 5.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.